Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
5.88
-0.36 (-5.77%)
May 23, 2025, 12:06 PM - Market open
Kura Oncology Stock Forecast
Stock Price Forecast
According to 10 professional analysts, the 12-month price target for Kura Oncology stock ranges from a low of $10 to a high of $40. The average analyst price target of $24.5 forecasts a 316.67% increase in the stock price over the next year.
Price Target: $24.50 (+316.67%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kura Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 5 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 10 | 10 | 10 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $32 → $30 | Buy | Maintains | $32 → $30 | +410.20% | May 19, 2025 |
| Barclays | Barclays | Buy Maintains $32 → $11 | Buy | Maintains | $32 → $11 | +87.07% | May 2, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $28 | Buy | Reiterates | $28 | +376.19% | Apr 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +580.27% | Apr 28, 2025 |
| UBS | UBS | Strong Buy Maintains $27 → $14 | Strong Buy | Maintains | $27 → $14 | +138.10% | Mar 6, 2025 |
Financial Forecast
Revenue This Year
146.51M
from 53.88M
Increased by 171.90%
Revenue Next Year
235.17M
from 146.51M
Increased by 60.51%
EPS This Year
-2.24
from -2.02
EPS Next Year
-2.13
from -2.24
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 460.5M | 473.8M | 385.4M | ||
| Avg | 146.5M | 235.2M | 178.3M | ||
| Low | 16.8M | 31.1M | 55.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 754.7% | 223.4% | 63.9% | ||
| Avg | 171.9% | 60.5% | -24.2% | ||
| Low | -68.9% | -78.8% | -76.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.25 | -0.48 | -0.15 | ||
| Avg | -2.24 | -2.13 | -2.15 | ||
| Low | -3.23 | -4.72 | -4.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.